Karyopharm Therapeutics to Participate in Upcoming Investor Conferences

NEWTON, Mass., Aug. 30, 2017 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:

• The Baird 2017 Global Healthcare Conference on Wednesday, September 6, 2017 at 1:25 p.m. ET at the InterContinental New York Barclay Hotel.
   
• The Cantor Fitzgerald Global Healthcare Conference on Monday, September 25, 2017 at 10:55 a.m. ET at the InterContinental New York Barclay Hotel.

A live webcast of each presentation will be available on the “Events & Presentations” page in the Investors section of the Company’s website at http://investors.karyopharm.com/events.cfm. A replay of each webcast will be archived on the Company's website for 30 days following the presentation.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).  The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330).  To date, over 2,100 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including in multiple myeloma in a pivotal, randomized Phase 3 study in combination with Velcade® (bortezomib) and low-dose dexamethasone (BOSTON), in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), and in diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others. Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with one or more approved therapies in a variety of tumor types to further inform the Company's clinical development priorities for selinexor.  In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.

Contacts:

Michelle Carroll
(212) 600-1902
[email protected]

Media:
Eliza Schleifstein
(917) 763-8106
[email protected]